ADMA Q1 2021 Earnings — ADMA Biologics, Inc. Revenue & Financial Results | Market Cap Arena

ADMAADMA Biologics, Inc.

$4B

Q1 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$16M+57.3% YoY

Gross Profit

-$2M-10.7% margin

Operating Income

-$15M-94.5% margin

Net Income

-$18M-114.5% margin

EPS (Diluted)

$-0.16

QoQ Revenue Growth

+15.0%

Cash Flow

Operating Cash Flow

-$33M

Free Cash Flow

-$36M

Stock-Based Comp.

$781,397

Balance Sheet

Total Assets

$236M

Total Liabilities

$123M

Stockholders' Equity

$113M

Cash & Equivalents

$62M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$16M	$10M	+57.3%
Gross Profit	-$2M	-$7M	+74.0%
Operating Income	-$15M	-$17M	+9.6%
Net Income	-$18M	-$19M	+4.5%